NO331551B1 - Isolert cytokin-zalpha11-ligand-polypeptid, isolert polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin - Google Patents

Isolert cytokin-zalpha11-ligand-polypeptid, isolert polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin Download PDF

Info

Publication number
NO331551B1
NO331551B1 NO20014364A NO20014364A NO331551B1 NO 331551 B1 NO331551 B1 NO 331551B1 NO 20014364 A NO20014364 A NO 20014364A NO 20014364 A NO20014364 A NO 20014364A NO 331551 B1 NO331551 B1 NO 331551B1
Authority
NO
Norway
Prior art keywords
cells
zalphall
amino acid
polypeptide
seq
Prior art date
Application number
NO20014364A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014364L (no
NO20014364D0 (no
Inventor
Richard D Holly
Cindy A Sprecher
Scott R Presnell
Julia E Novak
Angela K Hammond
Jane A Gross
Donald C Foster
Janet V Johnston
Andrew J Nelson
Stacey R Dillon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331551(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20014364D0 publication Critical patent/NO20014364D0/no
Publication of NO20014364L publication Critical patent/NO20014364L/no
Publication of NO331551B1 publication Critical patent/NO331551B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20014364A 1999-03-09 2001-09-07 Isolert cytokin-zalpha11-ligand-polypeptid, isolert polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin NO331551B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26490899A 1999-03-09 1999-03-09
US26599299A 1999-03-11 1999-03-11
US14201399P 1999-07-01 1999-07-01
PCT/US2000/006067 WO2000053761A2 (en) 1999-03-09 2000-03-09 Human cytokine as ligand of the zalpha receptor and uses thereof

Publications (3)

Publication Number Publication Date
NO20014364D0 NO20014364D0 (no) 2001-09-07
NO20014364L NO20014364L (no) 2001-11-09
NO331551B1 true NO331551B1 (no) 2012-01-23

Family

ID=27385745

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014364A NO331551B1 (no) 1999-03-09 2001-09-07 Isolert cytokin-zalpha11-ligand-polypeptid, isolert polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin
NO20111085A NO20111085L (no) 1999-03-09 2011-07-29 Isolert cytokin-zalphall-ligand-polypeptid, isolert Polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20111085A NO20111085L (no) 1999-03-09 2011-07-29 Isolert cytokin-zalphall-ligand-polypeptid, isolert Polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin

Country Status (23)

Country Link
EP (3) EP2295577A3 (cs)
JP (1) JP4405686B2 (cs)
KR (1) KR100743640B1 (cs)
CN (5) CN102406937A (cs)
AT (1) ATE377076T1 (cs)
AU (2) AU777842B2 (cs)
BR (1) BR0008772B1 (cs)
CA (1) CA2366921C (cs)
CZ (1) CZ302921B6 (cs)
DE (1) DE60036930T2 (cs)
DK (1) DK1165791T3 (cs)
ES (1) ES2295019T3 (cs)
HU (1) HU229148B1 (cs)
IL (5) IL145288A0 (cs)
MX (1) MXPA01009074A (cs)
NO (2) NO331551B1 (cs)
NZ (1) NZ514708A (cs)
PL (1) PL207350B1 (cs)
PT (1) PT1165791E (cs)
RU (1) RU2346951C2 (cs)
UA (1) UA84387C2 (cs)
WO (1) WO2000053761A2 (cs)
ZA (1) ZA017370B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CZ302921B6 (cs) * 1999-03-09 2012-01-18 Zymogenetics, Inc. Izolovaný polypeptid, fúzní protein, polynukleotid, expresní vektor, hostitelská bunka, protilátka, zpusob prípravy proteinu, protilátky, množení hematopoetických bunek, redukce proliferace neoplastických T a B bunek, stimulace imunitní odpovedi u sa
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
WO2003040313A2 (en) 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
PT1531850E (pt) * 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
EP1553982A4 (en) 2002-07-15 2008-03-26 Wyeth Corp METHOD AND COMPOSITIONS FOR MODULATING THE DEVELOPMENT AND FUNCTION OF T-HELPER CELLS (T sb H / sb)
BR0315134A (pt) * 2002-10-11 2005-08-16 Novo Nordisk As Usos de il-21 e de um polipeptìdeo de il-21
EP1731163A2 (en) * 2002-10-11 2006-12-13 Novo Nordisk A/S Treatment of allergic conditions by use of IL 21
DE60330044D1 (de) * 2002-12-13 2009-12-24 Zymogenetics Inc Il-21-produktion in prokaryontischen wirten
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
CA2529520A1 (en) * 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス, インコーポレイテッド Il−21を用いた自己免疫疾患の治療方法
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
DE602004029173D1 (de) * 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
EP1708737A2 (en) * 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
MXPA06008209A (es) 2004-01-21 2006-08-31 Novo Nordisk As Conjugacion de peptidos mediada por transglutaminasa.
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP2360181B1 (en) 2005-04-18 2013-09-18 Novo Nordisk A/S IL-21 variants
EP1963369B1 (en) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21 antagonists
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
JP2010512769A (ja) 2006-12-21 2010-04-30 ノヴォ ノルディスク アクティーゼルスカブ Il−21受容体との結合が変化したインターロイキン−21変異体
ES2572231T3 (es) 2007-12-07 2016-05-30 Zymogenetics Inc Anticuerpos monoclonales anti-IL-21 humana
PE20100141A1 (es) 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
AU2009248812A1 (en) 2008-05-23 2009-11-26 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
CN102021196B (zh) * 2009-11-20 2013-06-26 上海杰隆生物工程股份有限公司 毕赤酵母生产重组人白细胞介素21的方法
KR20150036186A (ko) 2012-06-27 2015-04-07 러트거즈,더스테이트유니버시티오브뉴저지 유세포 측정법을 이용한 rna 측정에 의한 t-세포 활성화에 대한 신속한 검정
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
ATE54167T1 (de) 1984-12-06 1990-07-15 Fina Research Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
WO1995007358A1 (en) 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
RU2220979C2 (ru) * 1993-08-12 2004-01-10 Иммьюнекс Корпорейшн ПОЛИПЕПТИД ЛИГАНДА flt3 (ВАРИАНТЫ), ПОЛИНУКЛЕОТИД(ВАРИАНТЫ), ЭКСПРЕССИРУЮЩИЙ ВЕКТОР(ВАРИАНТЫ), ЛИНИЯ КЛЕТОК СНО (ВАРИАНТЫ), СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА ЛИГАНДА flt3 (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ)
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
EP0889966A1 (en) 1995-11-09 1999-01-13 ZymoGenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
WO1998002536A2 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. Preparation of pichia methanolica auxotrophic mutants
IL128073A0 (en) 1996-07-17 1999-11-30 Zymogenetics Inc Transformation of pichia methanolica
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CZ302921B6 (cs) * 1999-03-09 2012-01-18 Zymogenetics, Inc. Izolovaný polypeptid, fúzní protein, polynukleotid, expresní vektor, hostitelská bunka, protilátka, zpusob prípravy proteinu, protilátky, množení hematopoetických bunek, redukce proliferace neoplastických T a B bunek, stimulace imunitní odpovedi u sa
US9418201B1 (en) 2015-11-19 2016-08-16 International Business Machines Corporation Integration of functional analysis and common path pessimism removal in static timing analysis

Also Published As

Publication number Publication date
PL207350B1 (pl) 2010-12-31
DE60036930T2 (de) 2008-10-09
WO2000053761A3 (en) 2000-12-21
WO2000053761A2 (en) 2000-09-14
EP1881070B1 (en) 2012-10-03
CZ20013184A3 (cs) 2002-04-17
DK1165791T3 (da) 2008-02-11
RU2004126135A (ru) 2006-02-10
CN101575377A (zh) 2009-11-11
PL351160A1 (en) 2003-03-24
IL145288A0 (en) 2002-06-30
EP1165791A2 (en) 2002-01-02
HU229148B1 (en) 2013-09-30
RU2346951C2 (ru) 2009-02-20
NO20014364L (no) 2001-11-09
BR0008772A (pt) 2002-05-07
PT1165791E (pt) 2008-01-16
DE60036930D1 (de) 2007-12-13
CA2366921A1 (en) 2000-09-14
AU777842B2 (en) 2004-11-04
NO20111085L (no) 2001-11-09
HUP0200418A2 (hu) 2002-05-29
CN1378595A (zh) 2002-11-06
IL195713A (en) 2010-11-30
CA2366921C (en) 2013-12-17
CN100500846C (zh) 2009-06-17
EP2295577A3 (en) 2012-08-08
EP1881070A3 (en) 2008-03-05
MXPA01009074A (es) 2002-03-27
AU3731200A (en) 2000-09-28
HUP0200418A3 (en) 2003-12-29
IL207424A (en) 2013-04-30
EP2295577A2 (en) 2011-03-16
NZ514708A (en) 2005-01-28
CN1927883B (zh) 2011-09-21
CN1927883A (zh) 2007-03-14
ZA017370B (en) 2002-06-26
CZ302921B6 (cs) 2012-01-18
NO20014364D0 (no) 2001-09-07
KR100743640B1 (ko) 2007-07-27
BR0008772B1 (pt) 2011-11-01
ATE377076T1 (de) 2007-11-15
JP2002537839A (ja) 2002-11-12
ES2295019T3 (es) 2008-04-16
AU2005200240A1 (en) 2005-02-17
KR20010103794A (ko) 2001-11-23
CN101575377B (zh) 2012-12-26
IL207403A (en) 2012-03-29
EP1165791B1 (en) 2007-10-31
CN102406937A (zh) 2012-04-11
JP4405686B2 (ja) 2010-01-27
EP1881070A2 (en) 2008-01-23
UA84387C2 (ru) 2008-10-27
CN1827639A (zh) 2006-09-06
IL145288A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
US7491800B2 (en) Cytokine zalpha11 ligand fusion proteins
NO20111085L (no) Isolert cytokin-zalphall-ligand-polypeptid, isolert Polynukleotid, ekspresjonsvektor, dyrket celle, fremgangsmate for fremstilling av peptidet, antistoff som binder til peptidet, anvendelse av preparat omfattende peptidet for fremstilling av medikament for behandling av sykdom, fremgangsmate for pavisning av peptidet i en biologisk prove samt polypeptidet for anvendelse innen medisin
US20070092485A1 (en) Cytokine zalpha11 ligand
RU2258710C2 (ru) Новый цитокин zalpha11-лиганд

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees